Evidence map›Paper›PMID 23838566›Full record

ArticleDevelopmental neuroscience2013

12/15-lipoxygenase expression is increased in oligodendrocytes and microglia of periventricular leukomalacia.

Robin L Haynes, Klaus van Leyen

Open access · bronzeAbstract read
In one paragraph

Article in Developmental neuroscience, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
6.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Robin L HaynesDepartment of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA. Robin.haynes@childrens.harvard.edu
Klaus van Leyen
Boston Children's Hospital · USMassachusetts General Hospital · US

Funding

PERIVENTRICULAR LEUKOMALACIA IN THE PREMATURE INFANTP01NS038475 · NINDS · CHILDREN'S HOSPITAL BOSTON · PI ROSENBERG, PAUL ALLEN · 2000 to 2009
$13.2M
Prenatal Alcohol Sudden Infant Death Syndrome/StillbirthU01HD045991 · NICHD · CHILDREN'S HOSPITAL BOSTON · PI KINNEY, HANNAH CHASE · 2003 to 2015
$8.4M
12-Lipoxygenase and Ischemic Brain Cell DeathR01NS049430 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI VAN LEYEN, KLAUS · 2005 to 2015
$3.6M
BRAINSTEM MATURATION IN THE SUDDEN INFANT DEATH SYNDROMER01HD020991 · NICHD · CHILDREN'S HOSPITAL BOSTON · PI HAYNES, ROBIN LYNN, KINNEY, HANNAH CHASE · 1986 to 2015
$3.3M
NIAAA NIH HHS L40 AA015226NICHD NIH HHS R01 HD020991NICHD NIH HHS U01 HD045991NINDS NIH HHS P01 NS038475NINDS NIH HHS P01-NS38475NINDS NIH HHS R01 NS049430
6 · The paper itself

Abstract

Oxidative stress involving premyelinating oligodendrocytes (OLs) is a major factor in the pathogenesis of preterm white matter injury. In animal and cell culture studies, activation of the lipid-oxidizing enzyme 12/15-lipoxygenase (12/15-LOX) plays a central role as an inflammatory mediator in the pathology of oxidative stress and OL cell death, as well as ischemia and neuronal death. The role of 12/15-LOX, however, is unclear in the developing human brain. The mechanism of 12/15-LOX involves the production of reactive oxygen species through the metabolism of arachidonic acid, as well as direct detrimental effects on organelle membranes. Here we tested the hypothesis that the density of 12/15-LOX-expressing cells is increased in periventricular leukomalacia (PVL). Using immunocytochemistry (ICC) in human paraffin-embedded tissue, 12/15-LOX expression was seen in macrophages of the focally necrotic lesions in the periventricular white matter, as well as in glial cells throughout the surrounding white matter with reactive gliosis. Interestingly, no significant 12/15-LOX expression was detected in neurons in the cerebral cortex overlying the damaged white matter. Using a scoring system from 0 to 3, we assessed the density of 12/15-LOX-expressing cells in diffusely gliotic white matter from 20 to 43 postconceptional (PC) weeks in 19 PVL cases (median = 36 PC weeks) and 10 control (non-PVL) cases (median = 34 PC weeks). The density of 12/15-LOX-positive cells was significantly increased in the diffuse component of PVL (score = 1.17 ± 0.15) compared to controls (score = 0.48 ± 0.21; p = 0.014). Using double-label ICC, 12/15-LOX was observed in PVL in OLs of the O4 and O1 premyelinating stages, as well as in mature OLs as determined with the mature OL marker adenomatous polyposis coli (APC). In addition, 12/15-LOX expression was present in a population of CD68-positive activated microglia. There was no 12/15-LOX expression in reactive astrocytes. Finally we observed terminal deoxynucleotide transferase dUTP nick end-labeling-positive cells within the white matter of PVL that expressed 12/15-LOX and/or within close proximity of 12/15-LOX-positive cells. Our data support a role for 12/15-LOX activation as an inflammatory mediator of injury in PVL, with a contribution of 12/15-LOX to PVL-induced damage to or cell death of OLs, including those at the O1 and O4 stages.

Indexed as

Arachidonate 12-LipoxygenaseArachidonate 15-LipoxygenaseHumansImmunohistochemistryInfant, NewbornIn Situ Nick-End LabelingLeukomalacia, PeriventricularMicrogliaOligodendroglia12-15-lipoxygenaseArachidonate 12-LipoxygenaseArachidonate 15-Lipoxygenase

Identifiers

PMID23838566
PMCPMC3860095
OpenAlexW2054319936

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.